Alterations, especially homozygous deletions, of the putative tumor suppressor gene, p16 (p16 INK4A , MTS1, CDKN2) have been found in tumor cell lines from a variety of neoplasms. Recent studies have reported frequent p16 gene deletions in cell lines from squamous cell carcinomas of the head and neck (SCCHN), although the prevalence of alterations was variable in primary tumors. This study determined the prevalence of point mutations and deletions of the p16 gene in 33 SCCHN. In addition, the association of p16 gene alterations and abnormalities of p53, PRAD-1 (cyclin D1), and the presence of human papillomavirus (HPV) was examined. We found an overall prevalence of p16 alterations of 36% (nine deletions, three single base substitutions, including one polymorphism). Seven tumors (of 29, 24%) had an alteration of p16 and p53; ®ve (of 33, 15%) had alterations of p16 and PRAD-1; three (of 29, 10%) had alterations of all three genes. In addition, of the ®ve tumors with human papillomavirus detected, only one also had a p16 gene alteration. The results indicate a potentially important role for the p16 gene in head and neck tumorigenesis. In addition, the presence of tumors with multiple somatic gene alterations suggest a possible interaction in the dysregulation of the cell cycle.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN, including oral cavity, pharynx and larynx) provides an excellent model for understanding the carcinogenic process due to the de®ned risk factors (tobacco and alcohol consumption) and emerging molecular characteristics. Cytogenetic, allelotyping, loss of heterozygosity, and gene ampli®cation studies have implicated 11q as the site of a putative oncogene, and 17p, 9p and 3p as sites of putative tumor suppressor genes in SCCHN (Cowan et al., 1992; Nawroz et al., 1994; Van der Reit et al., 1994) . Molecular studies have identi®ed candidate genes for these regions, namely cyclin D1 (PRAD-1, CCND1) as the protooncogene and p53 as a putative tumor suppressor gene (Brachman, 1994) . Recently, the cyclin-dependent kinase inhibitor, p16 (p16 INK4A , MTS1, CDKN2), has been proposed as the tumor suppressor gene at 9p21 (Serrano et al., 1993 Kamb et al., 1994; Nobori et al., 1994; Lukas et al., 1995a; Koh et al., 1995; Spillare et al., 1996) . Related CDK-inhibitors have also been isolated including p15 INK4b , p18 INK4C and p19 INK4d (Sherr and Roberts, 1995) . Further, the p16
INK4a locus yields two transcripts one encoding p16
INK4a and another encoding p19 ARF (Quelle et al., 1995) . All of these genes participate either directly or indirectly in the control of the cell cycle.
The transition from G 1 to S in the cell cycle relies on a coordinated interaction of several gene products including the retinoblastoma protein (Rb), cyclin D1, and its catalytic partners CDK4 and CDK6, and the cyclin-dependent kinase inhibitor, p16 (Peter and Herskowitz, 1994; Grana and Reddy, 1995; Yeudall and Jakus, 1995) . Loss of control of the G 1 to S transition is a common defect observed in many dierent tumor types and can occur through a variety of mechanisms (Hartwell and Kastan, 1994; Kamb, 1995) . Viruses that are associated with tumors, such as the human papillomavirus (HPV) and SV40, produce proteins that inactivate Rb and p53. Also, mutations and/or deletions of RB, p53, and p16 and ampli®cation and overexpression of cyclin D1 are relatively common events in a wide range of tumors. Recently, evidence for transcriptional repression of p16 through promotor methylation has been observed in all major solid tumor types, suggesting another mechanism through which loss of control of the G 1 -S transition can occur . It has been suggested that dierent genes related to the control of the cell cycle represent alternate targets and that functionally inactivating any one component will have the same consequence of loss of cell cycle control. Little research has been done to evaluate alternate pathways by examining the interrelationship among abnormalities in cell cycle genes in tumors. The relationship betwen p16 and other genes, including HPV has not been directly investigated in SCCHN.
Examination of primary tumors and cell lines for alterations of the p16 gene has yielded con¯icting results. Initial reports indicated a high frequency of homozygous deletions of p16 in a variety of cell lines (Kamb et al., 1994; Nobori et al., 1994) . In addition, point mutations were identi®ed in cell lines without deletions. Other studies using primary tumors reported a much lower prevalence of p16 deletions and mutations, suggesting that tumor cells might acquire p16 defects as a consequence of forming established lines (Carins et al., 1994; Spruck et al., 1994) . More recent studies suggest that p16 defects are not an artifact of establishing cell lines because they occur in a high percentage of certain types of primary carcinomas (Mori et al., 1994; Zhou et al., 1994; Caldas et al., 1994; Schmidt et al., 1994; Carins et al., 1995) . Two analyses of primary head and neck tumors have reported a prevalence of point mutations of 7% and 10%, con®rming that the loss of p16 function more commonly occurs through deletion (Carins et al., 1994; Zhang et al., 1994) . Two recent reports indicated a higher prevalence of p16 gene alterations in head and neck tumors 25% (16/65; all deletions; Carins et al., 1995) and 19% (7/36; six deletions; Lydiatt et al., 1995) . None of the studies of SCCHN evaluated the relationship between p16 gene alterations and the presence of alterations of other cell cycle associated genes.
In this study, we determined the prevalence of p16 somatic alterations in 33 SCCHN tumors and have examined the association of p16 mutation or deletion with aberrations of other tumor suppressor genes and oncogenes, and with the presence of human papillomavirus (HPV). Our results provide additional evidence for the role of the inactivation of p16 in the development of head and neck cancer.
Results
Among the 33 tumors examined, a total of 12 (36%) had either a deletion (n=9) or single base substitution in exon 2 of the p16 gene (n=3). Using dierential PCR, independently coampli®ed each time with a dierent set of reference genes (PGR/d-IFN, GAPDH/CPT), we detected p16 deletions in 9 (27%) of the tumors (Figure 1 and Table 1 ). Figure 2 shows an example of selected mutations. Four mutations were identi®ed in three tumors including an A4T transversion (GAC4GTC, Asp4Val) at codon 76 (case #2300), a G4A transition (GCG4ACG, Ala4Thr) at codon 140 (case #4165), and a tumor (case #3515) with two G4T transversion mutations, one at codon 79 (CGG4CTG, Arg4Leu), the other at codon 80 (GAG4TAG, Glu4Stop). Mutations at codon 76 have been reported in a previous study of head and neck tumors and in a study of esophageal cancer (Spruck et al., 1994; Mori et al., 1994) . In both cases, the sequence change was a transition from GAC to AAC; in our study the change was a transversion from GAC to GTC. The base substitution (GCG4ACG) at codon 140 has been reported in head and neck and other cancers and has been reported to be a population polymorphism (Cairns et al., 1994; Spruck et al., 1994; Mori et al., 1994) . The peripheral blood-derived DNA from this patient contained the same sequence alteration as in the tumor. A recent biochemical analysis found no functional eect of this mutation (Ranade et al., 1995) . Because it is suspected that the p16 mutation from this tumor (#4165) is a polymorphism it was excluded from the statistical comparisons. Germline DNA samples for the other two patients, whose tumors had a p16 base change, did not show any p16 mutations or deletions. Although there were some dierences, no signi®cant association was found between the presence of a p16 mutation and SCCHN site (P=0.74), recurrence status (P=0.43), or history of preoperative radio-or chemotherapy (P=0.42). Additionally, there was no relation between p16 alterations and Tumor-Node-Metastasis (TNM) stage classi®cation (P=0.47).
We were also able to successfully screen 29 of the 33 SCCHN tumors for p53 mutations using SSCP and direct sequencing. Twelve of 29 (41%) tumors were found to have a mutation of the p53 gene and seven of these 12 also had a p16 alteration (®ve deletions and two single base substitutions (P=0.15) ( Table 1) .
PRAD1 ampli®cation status was evaluated in all 33 tumors (Table 1) . Eight (24%) of the tumors had PRAD1 ampli®cation and ®ve of these also had a p16 deletion (P=0.10). There was no association between PRAD1 ampli®cation and a p53 mutation (P=0.53).
HPV was detected in ®ve of the 29 tumors (17%) for which a de®nitive HPV determination could be made (Table 1 ). All ®ve HPV-positive tumors were of HPV type 16. The presence of HPV was partially independent of alterations of the p16 gene, with only one tumor being both HPV-positive and having a p16 gene deletion (#3039). 
Discussion
The overall prevalence of p16 alterations found in this study was 33% (excluding the one p16 polymorphism), of which, nine (27%) were deletions and two (6%) were single base mutations. The prevalence of point mutations is very similar to Cairns et al. (1994) who found one of 15 primary head and neck tumors contained a single base mutation of p16 and marginally lower than the 10% ®gure of Zhang et al. (1994) . With respect to deletions, Zhang et al. did not ®nd any deletions among the 68 primary tumors they evaluated and Lydiatt et al. found six p16 gene deletions in 36 (17%) tumors. However, Cairns et al. (1995) recently reported that among 65 SCCHN tumors, 16 (25%) had a homozygous deletion. A common method of detecting p16 gene deletions is multiplex PCR which can be unreliable due to factors such as variable amounts of contaminating normal cells. In general it would be expected that this method would be conservative, that is, false negatives due to the appearance of bands resulting from the amplification of normal DNA would lead to an underestimate of the true prevalence of homozygous deletions. This may help explain the results of Zhang et al. whose samples were probably fresh tumor samples that most likely contained an unde®ned mixture of tumor and normal cells. In addition, they utilized a single and rather large reference gene (GAPDH, 474 bp) in comparison with the p16 target gene (around 200 bp).
If there is sucient degradation of the DNA from the tumor samples one would expect the appearance of false negatives. In addition, some deletions may be heterozygous rather than homozygous, although previous studies have not supported this possibility. As described in the Materials and methods section, we dissected ®xed tumor specimens allowing us to obtain tumor samples enriched for neoplastic cells. We also used a variation of multiplex PCR with two sets of reference genes, each set including one gene fragment larger and one smaller than the target gene. In addition, we performed a mixing experiment to assess our limits of detection, as well as demanding agreement among three independent reviewers. Nevertheless, this methodology will lead to some degree of underestimation of p16 deletions. It is encouraging that Cairns et al. (1995) reported a very similar estimate using other methods. They detected a homozygous deletion in 25% of their head and neck tumors (compared with 27% in this study) using analysis of microsatellite markers¯anking the p16 locus and uorescent in situ hybridization (FISH). The high proportion of deletions relative to point mutations has lead some to suggest that the target of deletion may be p16 and/or a neighboring gene, p15 (Hannon and Beach, 1994; Jen et al., 1994) . Fine mapping of deletions in bladder tumors has identi®ed a minimal region that includes p16, but not p15 (Cairns et al., 1995) . In addition, an analysis of p16 and p15 expression in oral tumor cell lines has indicated that 2  2  5  5  2  3  0  0  2  3  1  6  2  3  4  4  2  3  9  2  2  4  1  5  3  0  1  1  3  0  3  9  3  0  4  9  3  2  4  0  3  2  4  5  3  2  5  1 the inactivation of p16 may be of more signi®cance (Yeudall et al., 1994) . Deletions of p16 will also result in deletion of p19 ARF , a gene that shares exon 2 with p16
INK4a and also appears to be involved in cell cycle control (Quelle et al., 1995) . Further work is needed to more precisely de®ne the roles of p15, p16 and p19 ARF in SCCHN.
Recent research has provided new data on the role of various gene products in the regulation of the cell cycle, especially the biochemical pathway controlling progression through the G 1 phase. Abnormalities of these genes can lead to loss of control and tumorigenesis (Hartwell and Kastan, 1994) . It is generally assumed that genes such as p16, PRAD-1 (cyclin D1), CDK4 and RB are alternate targets in a common pathway and alteration of multiple genes is not necessary to provide further growth advantage for a tumor . The retinoblastoma gene (RB) appears to play a central role in the transition from the G 1 to S and its inactivation may completely eliminate this checkpoint (Weinberg, 1995) . It has been found that the loss of p16 in tumors is inversely related to the presence of a functional RB protein (Rb) (Okamoto et al., 1994; Shapiro et al., 1995; Aagaard et al., 1995; Lukas et al., 1995) . In addition, previous studies have shown that inactivation or Rb and overexpression of PRAD-1 are nonoverlapping in esophageal tumors (Jiang et al., 1993) . Lukas et al. (1995b) using cell lines, including SCCHN lines, have shown that concurrent abnormalities of cyclin D1 and p16 can cooperate in Rb-positive cells, but not in Rbnegative cells. Thus, one might expect to ®nd coexistent alterations of upstream eectors of Rb in some tumors.
Investigation of the relationship among these genes may be of particular interest in SCCHN, where mutational inactivation of Rb is infrequent (Yoo et al., 1994) . In our sample, only two tumors (3340, 3530) were found to lack expression of Rb as determined by immunostaining methods and both did not have any abnormalities of p53, p16, or PRAD-1. Although a statistically powerful analysis was not possible in this study we examined the potential interrelationship between p16 and other genes involved either directly or indirectly in regulation of the cell cycle including p53 and PRAD-1. Previous studies of SCCHN have not fully examined this complement of genes. Overall, we found of the 29 tumors that could be evaluated for alterations of p53, p16 and PRAD-1, three (10%) had an alteration of all three genes, six (21%) had two genes altered, and 11 (38%) had only one gene aected. Nine tumors (of 29, 31%) had an alteration of p16 and either p53 or PRAD-1. Of the eight tumors that had ampli®cation of PRAD-1, we found a p16 deletion in ®ve (62%) providing further evidence for a possible collaborative role of p16 and PRAD-1 in some tumors.
An analysis of p16 and p53 point mutations in a variety of cell lines has suggested that the two genes may act in independent pathways (Okamoto et al., 1994) . Another study of melanoma and bladder cancer cell lines and primary tumors did not ®nd that the coexistence of mutations in p53 and p16 was statistically signi®cant, although the study did not examine homozygous deletions of the p16 gene (Gruis et al., 1995) . In our study, alteration of p16 was not statistically signi®cantly associated with p53 mutation, although seven of 12 (58%) tumors with a p53 mutation also had a p16 mutation. The Zhang et al. study found that all the cell lines with a deleted or mutated p16 gene also had a mutated p53 gene; three of the eleven primary tumors with a mutation of p16 also had a p53 mutation. Neither this study nor the study of Zhang et al. examined p16 promoter methylation as a mechanism of p16 inactivation. Further studies examining all mechanisms of p16 inactivation may clarify the relationship between p16 and p53 in head and neck tumors.
Our study is the ®rst to evaluate the relationship between p16 and HPV in tumors. The lack of a positive association between the presence of HPV and mutations or deletions of p16 and ampli®cation of PRAD-1 extends the previously reported independence Table 1 (Munger et al., 1989; Schener et al., 1990) . Binding with these proteins appears to result in loss of cell cycle control and genomic instability (White et al., 1994; Xiong et al., 1996) . One would not expect to ®nd many p16 gene alterations in tumors in which Rb inactivation had occurred by means of binding with HPV oncoprotein, analogous to the inverse correlation seen between p16 and Rb in tumors with inactivating mutations of RB. A recent study of p16 and HPV in cervical carcinoma cell lines provides additional support for this hypothesis (Kelley et al., 1995) . In summary, using primary tumors, we have provided additional support for the importance of p16 alterations in SCCHN. Our ®ndings also suggest that a single tumor can harbor alterations of multiple genes involved in cell cycle control. Further work is needed to clarify the relative importance and functional consequences of alterations of p16 and other genes involved in the regulation of the cell cycle. Future work should also take into account the new ®ndings that inactivation of the p16 gene by methylation may represent an important pathway in the genesis of head and neck tumors . Finally, molecular epidemiologic studies are also needed to evaluate whether SCCHN risk factors such as tobacco and alcohol are related to p16 gene mutation and deletion.
Materials and methods

Tumour samples
A total of 33 tumors from patients diagnosed with either primary (n=23) or recurrent (n=10) squamous cell carcinoma of the head and neck at the University of North Carolina Hospitals was obtained. Informed consent was obtained from all patients for the use of tissue samples in research.
DNA extraction
Molecular analyses were carried out on DNA puri®ed from 10 mM sections of formalin-®xed paran-embedded tumors. These tumor sections were subjected to pathologic review in which tumor areas were identi®ed, tumorenriched tissue isolated from slides, and DNA extracted using a standardized protocol (Wright and Manos, 1990 ).
p53 and p16 mutation screening
Tumors were screened for mutations in p53 exons 4 ± 8 and p16 exon 2. Analyses were performed on DNA isolated DNA lysates prepared from tumor-enriched formalin-®xed paran-embedded tumor tissue and were veri®ed using DNA extracted from snap frozen tumors. All PCR, SSCP and sequencing primers are given in Table 2 .
The following segments of the p53 gene were ampli®ed in separate PCR reactions to generate template for both SSCP ± PCR and sequencing: exon 4, exons 5 and 6, and exons 7 and 8. PCR was carried out in a 50 ml reaction mixture containing 100 ng genomic DNA, 500 nM each primer, 16 Cetus buer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 and 0.001% gelatin), 200 mM each deoxyribonucleotide and 2.5 units AmpliTaq DNA polymerase (Perkin Elmer.) Amplification was performed using 32 cycles of: 948C for 30 s, 608C for 30 s and 728C for 30 s with a ®nal extension of 728C for 10 min. Exon 2 of the p16 gene was ampli®ed under similar conditions but with 5% dimethylsulfoxide (DMSO), an annealing temperature of 558C and 34 cycles of amplification. We have not evaluated exon 1 of the p16 gene owing to the fact that there are a paucity of mutations reported for this exon and all missense mutations that have been proven to functionally inactivate the p16 protein reside in exon 2.
SSCP-PCR was performed on p53 exons 5, 6, 7 and 8, using ®rst PCR products as template. Because of its size, exon 4 was divided into two segments (4-1 and 4-2) for SSCP. Exon 2 of p16 was analysed directly from genomic DNA as three separate fragments. SSCP ± PCR reactions consisted of a total volume of 20 ml containing 500 nM primers, 16 Cetus buer, 200 mM each dNTP, 2.5 units AmpliTaq polymerase and 100 mCi/ml [ 32 Pa]dCTP. Cycle conditions for p53 were as described for ®rst PCR. The p16 SSCP ± PCR reaction conditions were the same as for p53 except that 5% DMSO was added and an annealing temperature of 558C was used.
SSCP ± PCR products were diluted 30-fold with 1% SDS/ 10 mM EDTA, the diluted product (3 ml) was mixed with an equal volume of stop buer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and denatured at 948C for 5 min. SSCP reaction products were subjected to electrophoresis in 6% polyacrylamide nondenaturing gels, both at room temperature (these gels included 5% glycerol) and at 48C. Negative control samples containing only wild type p53 or p16 genes were included on each gel. In addition, all experiments were run using a blank control without template DNA and none showed ampli®ed products due to outside contamination.
Tumors showing altered SSCP bands were further analysed as follows. The ®rst PCR product or gel-puri®ed abnormal SSCP bands were used as template for asymmetric PCR to generate single forward and reverse DNA strands. Asymmetric PCR was carried out under PCR conditions previously described but with primer concentrations of either 500 nM forward primer with 10 nM reverse primer or 10 nM forward primer with 500 nM reverse primer. Both forward and reverse asymmetric PCR products were puri®ed and used as template in sequencing reactions. Samples were determined to be positive only if both strands exhibited the same mutation. Mutations were veri®ed by repeating the entire sequencing analyses on suspected positive samples.
PRAD-1 ampli®cation
The method of binary dierential PCR (Liu et al., 1993) was used to identify tumors with ampli®cation of the PRAD-1 (cyclin D1) gene. Gene ampli®cation was evaluated using both a 127 bp fragment of PGR (progesterone receptor gene) and an 85 bp fragment of d-IFN (d interferon gene) as references for the 101 bp fragment of PRAD-1. Each dierential PCR reaction contained PRAD-1 as the target gene and one reference gene. We used additional reference loci (GAPDH, CPT) to verify ampli®cation in possible positive samples, and ampli®cation was performed at least twice for each reference gene on apparent positives. In addition, we used the FaDu cell line, which carries an approximately 10-fold level of PRAD-1 ampli®cation, as a positive control. Typically, our positive samples showed a 5 ± 10-fold level of ampli®cation. Primer sequences for dierential PCR are given in Table 2 . Reactions were carried out in a 50 ml reaction mixture containing 100 ng genomic DNA or 2 ± 4 ml DNA lysate, 16 Cetus buer, 200 mM dNTPs, 2.5 units AmpliTaq. Primer concentrations were determined empirically and depended upon both the combination of target and reference gene as well as the oligonucleotide lot used. PCR cycle conditions were 34 cycles of 948C for 30 s, 608C for 30 s and 728C for 30 s and a ®nal extension of 728C for 10 min. PCR products were separated in 6% polyacrylamide minigels at 100 volts for 70 min, then were stained with ethidium bromide and photographed.
p16 deletion
The method of layered dierential PCR was used to identify tumors with deletion of the p16 gene. Layered PCR involves performing two separate binary PCR reactions with each binary reaction containing the p16 target primers and one reference primer set. Deletions were evaluated using each of two pairs of reference genes (Table  2) . One pair consisted of a 127 bp fragment of PGR (Progesterone receptor gene) and an 85 bp fragment of d-IFN as references for the 101 bp p16 fragment. The second pair consisted of a 125 bp fragment of GAPDH (glyceraldehyde phosphate dehydrogenase gene) and an 85 bp fragment of CPT1 (carnitine palmitoyl-transferase) as references for the p16 target. To minimize variability, the reactions for both reference genes in the pair are run simultaneously and in the same PCR machine, using the same reagents. PCR products were separated in 6% polyacrylamide minigels at 100 volts. The product with the smaller of the two reference fragments of the pair is loaded ®rst and run into the gel for 10 min. Next, the product with the larger reference is loaded on top of the smaller. The gel is run for 60 min, then stained with ethidium bromide and photographed. A deletion was considered to be present if both sets of reference genes independently showed a reduction in the intensity of the p16 band as determined by the consensus of three independent reviewers.
To examine the potential problem of failing to detect a homozygous deletion because of the contamination of tumor samples by normal cells we conducted an additional mixing experiment. Cells with a known homozygous deletion of p16 (K562) were mixed in varying proportions (0%, 20%, 40%, 60% and 80%) with untransformed human foreskin ®broblast cells. The cell mixture was then paranembedded and DNA was extracted from sections as described above. In addition, gels were photographed and scanned by a laser densitometer. The intensity of the p16 band and the reference gene band was determained and an intensity ratio (P16/reference) derived. Comparison of the p16/CPT ratios and estimated percentage of normal cells for the representative tumors in Figure 1a with the cell mixture experiment data in Figure 1b shows that the qualitative threshold we used to classify samples corresponds quite well with the ratio expected with approximately 60% normal cell 
HPV methods
Ten micron tissue sections were cut for the analysis of HPV DNA sequences by PCR. A section of appendix tissues was cut at the beginning, end and after every ®ve specimens to serve as a negative processing control. Tissues were extracted and digested as previously described (Wright and Manos, 1990) . Co-ampli®cations of a 268 bp b-globin product and a 450 bp HPV L1 gene product were performed (Bauer et al., 1992) . Separate ampli®cation reactions for a 536 bp b-globin fragment were also performed and served as a measure of DNA integrity and sample suciency (Table 2) . DNA extracted from the SiHa cervical carcinoma cell line served as a positive control and a negative control without DNA was included. Amplification products were initially analysed on 1% agarose gels, then spotted onto Biodyne B nylon membranes for dot-blot hybridization. Replicate blots were probed with biotinlabeled probes; a b-globin oligonucleotide; a generic HPV probe; and HPV type-speci®c oligonucleotides (HPV types 6, 11, 16, 18, 31, 33, 35, 39 and 45) . Blots were hybridized as described and detected by binding with streptavidinhorseradish peroxidase (Vector Laboratories), followed by incubation with ECL chemiluminescent reagents (Amersham Corp.). Blots were exposed to X-ray ®lm (Kodak XAR-5) for 5 min and 2 h.
Statistical analysis
To evaluate the relationship between p16 alterations and somatic mutations in p53, ampli®cation of PRAD-1, or the presence of HPV, we calculated standard chi-square statistics for contingency tables employing exact testing methods.
